Dr Scott Ledger

Dr Scott Ledger

Research Associate
  • 2011 - 2016: PhD Candidate – University of New South Wales, Faculty of Medicine. PhD awarded July 2016.
  • 2005 - 2009: Bachelor of Science (Honours, 1st Class) – University of New South Wales
Medicine & Health
The Kirby Institute
+61-02-9385 0113
  • Book Chapters | 2019
    Ognenovska K; Klemm V; Ledger S; Turville S; Symonds G; D. Kelleher A; L. Ahlenstiel C, 2019, 'Mechanisms for Controlling HIV-1 Infection: A Gene Therapy Approach', in In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders, IntechOpen, http://dx.doi.org/10.5772/intechopen.79669
    Book Chapters | 2018
    Ognenovska K; Klemm V; Ledger S; Turville S; Symonds G; Kelleher A; Ahlenstiel CL, 2018, 'Mechanisms for Controlling HIV-1 infection: a Gene Therapy Approach', in In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders, http://dx.doi.org/10.5772/intechopen.72962
    Book Chapters | 2011
    Ledger S; Savkovic B; Millington ML; Impey H; Boyd M; Murray JM; Symonds G, 2011, 'Cell-delivered gene theraphy for HIV', in Tang Y (ed.), Recent Translational Research in HIV/AIDS, InTech, Croatia, pp. 405 - 430, http://dx.doi.org/10.5772/22658
  • Journal articles | 2023
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C, 2023, 'Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2', Antiviral Research, 217, http://dx.doi.org/10.1016/j.antiviral.2023.105677
    Journal articles | 2022
    Agbosu EE; Ledger S; Kelleher AD; Wen J; Ahlenstiel CL, 2022, 'Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection', Pharmaceutics, 14, http://dx.doi.org/10.3390/pharmaceutics14071352
    Journal articles | 2022
    Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL, 2022, 'Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract', International Journal of Molecular Sciences, 23, http://dx.doi.org/10.3390/ijms23052408
    Journal articles | 2018
    Ledger S; Howe A; Turville S; Aggarwal A; Savkovic B; Ong A; Wolstein O; Boyd M; Millington M; Gorry PR; Murray JM; Symonds G, 2018, 'Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46', Journal of Gene Medicine, 20, http://dx.doi.org/10.1002/jgm.3006
    Journal articles | 2018
    Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD, 2018, 'RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency', Retrovirology, 15, pp. 67, http://dx.doi.org/10.1186/s12977-018-0451-0
    Journal articles | 2017
    Zaunders J; Howe A; Ledger S; Kelleher A; Murray J; Symonds G, 2017, '23 Knockdown of CCR5 expression in antigen-specific cytotoxic CD4 T cells', Journal of Virus Eradication, 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30728-7
    Journal articles | 2015
    Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G, 2015, 'CCR5 targeted cell therapy for hiv and prevention of viral escape', Viruses, 7, pp. 4186 - 4203, http://dx.doi.org/10.3390/v7082816
    Journal articles | 2014
    Savkovic B; Nichols J; Birkett D; Applegate T; Ledger S; Symonds G; Murray JM, 2014, 'A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells', PLoS Computational Biology, 10, http://dx.doi.org/10.1371/journal.pcbi.1003681
  • Conference Posters | 2012
    Ledger S; Savkovic B; Murray JM; Symonds GP; Ledger S, 2012, 'Short-hairpin RNA to CCR5 and its effect on HIV susceptible culture through the use of a lentiviral vector', Melbourne, Australia, presented at Australasian HIV/AIDS Conference 2012, Melbourne, Australia, 17 October 2012 - 19 October 2012, http://secure.ashm.org.au/ei/viewpdf.esp?id=101&file=c:%5CCertain%5CEventwin%5Cdocs%5Cpdf%5CCA12AFinal00112.pdf

Kirby Emerging Investigator Award - 2021 - $10,000


My research Includes investigating:

The use of siRNA to treat acute SARS-CoV-2 infection.

The use of lentiviral gene therapies to treat/manage HIV infection, with a main focus on using shRNA, as well as anti-HIV genes.

Investigating the use of siRNA to treat other viral infections such as HTLV-1, HPV, EBV, and where relevant, their their associated virus-caused cancers, such as cervical cancer (HPV).